Solid Third Quarter Performance
Humana delivered a solid third quarter in line with expectations, with medical cost trends and full year 2025 EPS outlook of approximately $17 being reaffirmed.
Improvement in Channel and Product Mix
New sales are at the high end of the anticipated range, with improved channel mix and favorable product mix including higher than expected sales in plans with 4 stars or greater.
Operational Efficiency Initiatives
Partnership with Genpact to outsource finance capabilities and introduction of an AI platform expected to generate over $100 million in savings while improving operations.
Capital Allocation and Strategic Investments
Asset sale of Enclara Pharmacia and ongoing efforts to sell additional non-core assets to free up capital. Acquisition efforts in the Villages Health and development of CenterWell Pharmacy strategies.
Better Retention and Sales Driving Membership
Increased retention and better-than-expected sales in the current year, contributing to improved membership numbers.